accessed 10.09.2023) in cancer and is, so far, the most clinically advanced and promising drug reactivating mutant p53 in myeloid malignancies to date. The clinical trials showed that eprenetapopt has a favorable safety profile. It exhibits antitumor activity even against tumors that ...